Social Media Ideas for Antibody-Drug Conjugates

Latest updates for Antibody-Drug Conjugates

Fresh curated links around Antibody-drug conjugates are collected here so marketers can spot useful updates and turn timely ideas into posts faster.

Post angles to try

Share the most useful takeaway for your audience.

Turn one article into a quick practical checklist.

Ask your audience how this shift affects their work.

Turn angles into scheduled posts

Fresh articles and ideas

Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.

bioengineer.org /3 weeks ago

Cracking the Code: How Cancer Evades Antibody-Drug Conjugates and New Strategies to Overcome Resistance

Antibody-drug conjugates (ADCs) have emerged as revolutionary agents in oncology, representing a precision-guided approach that targets cancer cells with high specificity while min...

Read source

bioengineer.org /1 month ago

Advances and Strategies in Antibody-Oligonucleotide Conjugates

In the swiftly evolving landscape of gene therapy, antibody-oligonucleotide conjugates (AOCs) have emerged as a transformative platform primed to revolutionize targeted molecular d...

Read source

genengnews.com /1 month ago

Mutating Antibodies for Easier Drug-Conjugate Manufacturing

Mutations engineered into antibodies could help companies developing the next generation of antibody-drug conjugates by providing convenient general-purpose “lock-on” locations for...

Read source

biopharmadive.com /1 month ago

A Spanish biotech banks $87M to make differentiated ADCs

Ona Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced forms of breast and colorectal cancers.

Read source

medcitynews.com /1 month ago

AbbVie’s ADC Strategy Notches Another Win With FDA Approval in Ultra-Rare Blood Cancer

AbbVie drug Decnupaz received FDA approval for treating blastic plasmacytoid dendritic cell neoplasm, or BPDCN. This antibody drug conjugate came from AbbVie’s 2023 ImmunoGen acqui...

Read source

genengnews.com /2 days ago

Analytical Challenges for Antibody-Drug Conjugate (ADC) Manufacturing

This collection of articles and expert perspectives explores the critical challenges shaping ADC development today, from analytical strategy and impurity control to linker technolo...

Read source

journals.plos.org /1 month ago

Agent-based modeling demonstrates how target-independent processes supplement killing by antibody-drug conjugates in can...

by Melissa C. Calopiz, Jennifer J. Linderman, Greg M. Thurber Antibody-drug conjugates (ADCs) have had remarkable clinical success in recent years with multiple new approvals. How...

Read source

webwire.com /1 week ago

Enhertu approved in the EU as first tumour agnostic HER2-directed therapy and antibody drug conjugate for patients with...

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unrese...

Read source

genengnews.com /1 month ago

Stipple Bio and Lonza Agree to Focus on Advancing Oncology ADC Therapies

This collaboration between Stipple Bio and Lonza combines the former’s epitope discovery capabilities with the latter’s GlycoConnect antibody conjugation technology, HydraSpace pol...

Read source

fiercebiotech.com /1 month ago

ASCO: Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice

The first-in-class EGFRxHER3 bispecific ADC that BMS paid $800 million for has shown strong phase 3 results from China that suggest it could put up a fight against blockbuster TROP...

Read source

biopharmadive.com /1 month ago

ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer

At the year’s biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made headway against a once-insurmountable foe.

Read source

law360.com /2 weeks ago

Key Tips For Patenting Antibody-Drug Conjugate Inventions

Recent decisions highlight the significant challenges that can arise when patenting antibody-drug conjugates, which require strategic considerations for satisfying heightened writt...

Read source

cafepharma.com /1 month ago

May 28 2026 - AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer

May 28 2026 - AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer admin Thu, 05/28/2026 - 11:51 Steady progress across the board today, with new appro...

Read source

medcitynews.com /1 month ago

AstraZeneca, Daiichi Drug Approved as New First-Line Therapy for Tough Type of Breast Cancer

Datroway landed its third FDA approval in the past 18 months, this time as a treatment for triple negative breast cancer. The antibody drug conjugate was developed under a broad co...

Read source

fiercebiotech.com /1 month ago

Innovent, fresh from $1.2B deal, posts phase 3 win for Takeda-partnered ADC

Innovent Biologics has reported a phase 3 victory for IBI343, boosting the prospects of an antibody-drug conjugate (ADC) that Takeda bet big on last year.

Read source

cafepharma.com /1 month ago

ADC Therapeutics

ADC Therapeutics Anonymous (not verified) Sun, 06/07/2026 - 17:48 field_thread_url https://cafepharma.com/boards/threads/adc-therapeutics.665008/...

Read source

biopharmadive.com /5 days ago

GSK, Hansoh ADC extends survival in lung cancer study

GSK claimed the result was a first for an ADC aimed at the “B7-H3” protein, an increasingly popular target of late among cancer drugmakers.

Read source

fiercebiotech.com /1 week ago

Whitehawk swoops in for five ADCs via development deal with China's Biocytogen

Biocytogen and Whitehawk Therapeutics are joining forces to develop bispecific antibody-drug conjugates using Biocytogen's discovery platform.

Read source

genengnews.com /1 month ago

Regeneron, Parabilis Ink Up-to-$2.3B Antibody-Peptide Conjugate Collaboration

Regeneron will marry its antibody capabilities with Parabilisâ€™ stabilized helical peptide or Heliconâ„¢ platform, with the goal of developing both Antibody-Heliconâ„¢ Conjugates...

Read source

medcitynews.com /1 month ago

Startup Secures $86M to Take On One of the Challenges for ADCs in Breast Cancer

Ona Therapeutics’ antibody drug conjugates come from a platform technology that discovers novel antigens intended to enable the therapies to overcome drug resistance. The Spain-bas...

Read source

biopharmadive.com /1 week ago

Novartis to acquire ADC developer in a deal worth up to $1.5B

The deal hands over two ADCs with a different mechanism of action targeting cell growth, and marks Novartis' entry into ADC development.

Read source

genengnews.com /2 weeks ago

InduPro Licenses Lonza’s Linker Payload Technologies and Bioconjugation Platforms

Lonza and InduPro signed the licensing agreement to develop differentiated therapeutic approaches designed to address complex diseases such as cancer, where precision targeting and...

Read source

genengnews.com /1 week ago

Novartis to Acquire Myricx Bio for Up to $1.5B, Adding Cancer-Fighting ADC Payload Platform

Myricx Bio specializes in developing ADCs that use N-myristoyltransferase inhibitor (NMTi) payloads, an approach designed to deliver a differentiated cancer-killing payload directl...

Read source

medcitynews.com /3 weeks ago

New FDA Nod Keeps Gilead Drug Competitive With AstraZeneca & Daiichi in Breast Cancer

Gilead Sciences antibody drug conjugate Trodelvy is now approved as a first-line treatment for triple-negative breast cancer. This expanded approval for Trodelvy comes with a sligh...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.